NewsArs Technica

Ranked by formulaVerdict: Routine

The FDA wants to pull its approval of a drug. It’s not so easy

The regulator says Tavneos was approved on the basis of manipulated study data.

By Talpos, Magazine

Score█████░░░░░4.8

Caveats

  • Not randomized: its findings are associations.

VerdictCompetent work. Briefs at most.

Read at Ars Technica

Summary from the source

The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?

Sara Talpos, Undark Magazine

The editor's rubric

Heuristic review

Leverage2 / 5
Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
15% of this desk’s rubric
Magnitude2 / 5
Solid incremental gain on a meaningful problem.
20% of this desk’s rubric
Evidence2 / 5
Limited: single setting, weak baselines, or an observational association presented as causal.
20% of this desk’s rubric
Novelty2 / 5
A new combination of known ideas.
10% of this desk’s rubric
Trajectory2 / 5
Some room to improve with obvious engineering.
10% of this desk’s rubric
Stakes2 / 5
Benefits a professional community (practitioners, clinicians, engineers).
25% of this desk’s rubric

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. No strong cues found. Red flags: not randomized.

How the score was computed

rank-2026-10-18

Score█████░░░░░4.8

Score = 10 × (50% × adjusted merit / 10 + 25% × attention + 25% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit
3.4 / 10
Weighted rubric, evidence-gated.
Adjusted merit
3.8 / 10
Shrunk toward the desk prior by editor confidence (30%).
Attention
24%
Citations, upvotes, points, mentions.
Freshness
93%
Half-life decay since publication.

No attention signals recorded yet.

The record

  • Reviewed by heuristic-v10 on Oct 31, 2026, 12:58 UTC. Paper type: news.
  • Categories: Science, fda, syndication
  • BRIEF, No.3 in the Front page edition of October 31, 2026.
  • TOP, No.2 in the News edition of October 31, 2026.